Categories
- All
- Animal & Veterinary
- Award
- Biologics
- Coronavirus
- Cosmetics
- Design
- Dietary Supplements
- Drugs
- Follow @FDAmedia on Twitter
- Follow @FDAMedia on X
- Follow @US_FDA on Twitter
- Follow @US_FDA on X
- Follow FDA on Facebook
- Food & Beverages
- Healthy
- Hotel
- Infant Formula & Foods
- Infectious Disease
- Lifestyle
- Medical Devices
- Nature
- Office
- Over-the-Counter Drugs
- Tobacco
- Training
- Travel Tips
- Travel Tips
- Vaccines
117 articles found
-
FDA Approves New Buprenorphine Treatment Option for Opioid Use DisorderToday, the U.S. Food and Drug Administration approved Brixadi (buprenorphine) extended-release injection for subcutaneous use (under the skin) to treat moderate to severe opioid use disorder (OUD). Br... -
FDA Roundup: May 23, 2023Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Monday, the FDA and the Veterans Health Administration announced a new collaboration...
-
FDA Approves Prescription Nasal Spray to Reverse Opioid OverdoseToday, the U.S. Food and Drug Administration approved Opvee, the first nalmefene hydrochloride nasal spray for the emergency treatment of known or suspected opioid overdose in adults and pediatric pat...
-
FDA Roundup: May 19, 2023Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced that the National Academies of Sciences, Engineering, and Medi...
-
FDA Roundup: May 16, 2023Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA updated its new Rumor Control page to provide the facts and inform the p...
-
FDA Roundup: May 12, 2023Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA updated information on medical device shortages on the FDA.gov website t...
-
FDA Approves Novel Drug to Treat Moderate to Severe Hot Flashes Caused by MenopauseToday, the U.S. Food and Drug Administration approved Veozah (fezolinetant), an oral medication for the treatment of moderate to severe vasomotor symptoms, or hot flashes, caused by menopause. Veozah...
-
FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia due to Alzheimer’s DiseaseToday, the U.S. Food and Drug Administration is announcing the supplemental approval of Rexulti (brexpiprazole) oral tablets for the treatment of agitation associated with dementia due to Alzheimer’s...
-
FDA Roundup: May 09, 2023Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: On Friday, the FDA granted marketing authorization of the VITROS Immunodiagnostic Produ...
-
FDA Roundup: May 05, 2023Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA issued a safety communication to warn consumers and health care pro...